• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: An accelerated approach toward epitope-driven vaccine development

Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: An accelerated approach toward epitope-driven vaccine development

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2014 Jun 24;10(8). [Epub ahead of print] Full Text
Smarter vaccine design will circumvent immunoregulatory evasion in chronic HIV and HCV infection

Smarter vaccine design will circumvent immunoregulatory evasion in chronic HIV and HCV infection

by Adam | Oct 22, 2016

In: Why vaccines to HIV, HCV and Malaria have so far failed – challenges to developing vaccines against immunoregulating pathogens. Frontiers in Microbiology. 2014. Editor (Gowans).
Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity

Tregitope Applications to Tolerance Induction in Autoimmune Disease and Therapeutic Protein Immunogenicity

by Adam | Oct 21, 2016

Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease

Albumin Delivery of Tregitope Peptides for Tolerance Induction in Autoimmunity and Inflammatory Disease

by Adam | Oct 21, 2016

T-Cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation

T-Cell Dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation

by Adam | Oct 21, 2016

« Older Entries
Next Entries »

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.